When Amgen Inc. (NASDAQ: AMGN) released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue. That compared with consensus estimates of $3.53 in EPS and $5.63 billion in revenue, as well as the $3.69 per share on $5.9 billion posted in the same period from last year.
During the most recent quarter, revenues decreased 3% year over year, reflecting the impact of biosimilar and generic competition against key products. Product sales fell 1% in the period as well.
In terms of its product sales, Amgen reported as follows:
- Prolia sales increased 18% year over year to $630 million
- Evenity sales were $59 million
- Repatha sales increased 40% to $168 million
- Aimovig sales were $66 million
- Parsabiv sales increased 54% $157 million
- Kyprolis sales increased 15% to $266 million
- Xgeva sales increased 10% to $476 million
- Vectibix, sales increased 8% to $196 million
- Nplate sales increased 10% to $195 million
- Blincyto sales increased 47% to $85 million
- Biosimilar sales were $173 million.
- Enbrel sales increased 6% to $1.37 billion
- Neulasta sales decreased 32% to $711 million
- Neupogen sales decreased 36% to $54 million
- Epogen sales decreased 15% to $215 million
- Aranesp sales decreased 5% to $452 million
- Sensipar/Mimpara sales decreased 73% to $109 million
Looking ahead to the full year, the company expects to see EPS in the range of $14.20 to $14.45 and revenue between $22.8 billion and $23.0 billion. Consensus estimates are calling for $14.39 in EPS and $22.85 billion in revenue for the year.
Robert A. Bradway, board chair and chief executive, commented:
Amgen continues to execute well in a dynamic environment, with many of our innovative medicines delivering double-digit, volume-driven growth, complemented by the strong performance of our recently launched biosimilar products. We continue to advance numerous first-in-class medicines in our pipeline, while also pursuing external opportunities that will contribute to our long-term growth, such as our pending acquisition of Otezla.
Shares of Amgen closed Tuesday at $208.99, with a 52-week range of $166.30 to $211.90. The consensus price target is $215.62. Following the announcement, the stock was initially flat in the after-hours trading session.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
